ICL Reports Mixed 2025 Results Amid Strategic Shifts
Event summary
- ICL reported $1.7B in Q4 2025 sales, up 6% YoY, but operating income fell to -$16M from $147M in 2024.
- Full-year 2025 sales reached $7.2B, up 5% YoY, with adjusted EBITDA up 1% to $1.5B.
- ICL incurred $239M in Q4 adjustments, including $122M for strategic realignment and $80M for water extraction fees.
- The company acquired 49.9% of Bartek Ingredients in January 2026 for $60M.
- ICL expects 2026 adjusted EBITDA between $1.4B and $1.6B.
The big picture
ICL's 2025 results reflect a mixed performance amid strategic shifts. The company is focusing on its core growth engines—specialty crop nutrition and specialty food solutions—while navigating regulatory challenges and market dynamics. The acquisition of Bartek Ingredients underscores its commitment to expanding its specialty food solutions portfolio. However, the company's ability to sustain profitability and execute its strategic realignment will be key to its long-term success.
What we're watching
- Strategic Execution
- ICL's ability to successfully implement its new strategy, including the discontinuation of LFP battery materials projects and the focus on specialty crop nutrition and food solutions, will be critical to its future performance.
- Market Dynamics
- The company's growth engines—specialty crop nutrition and specialty food solutions—will drive improvement, but the pace of M&A and geographic expansion remains uncertain.
- Regulatory Compliance
- ICL's compliance with environmental regulations, particularly regarding water extraction fees in the Dead Sea concession area, could impact its operational costs and profitability.
Related topics